ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second chance radiation: can we safely treat breast cancer again?
Disease control Recruiting nowThis study is testing whether giving radiation treatment a second time is safe for women whose breast cancer has returned in the same breast. Researchers want to understand both the benefits and risks of this approach for patients who have already had radiation therapy. The study…
Matched conditions: ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Phase: NA • Sponsor: Youssef Zeidan • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for younger women: drug combo aims to shrink tumors before surgery
Disease control Recruiting nowThis study is testing a new drug combination for premenopausal women with a common type of breast cancer (ER+/HER2-) before they have surgery. The goal is to see if taking the drug (Z)-endoxifen with a monthly injection (goserelin) can slow or stop tumor growth, potentially shrin…
Matched conditions: ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Atossa Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New hope for Tough-to-Treat breast cancer: can a drug combo outperform a single pill?
Disease control Recruiting nowThis study is for people with advanced or metastatic breast cancer that is estrogen-receptor-positive and HER2-negative, and whose cancer has grown despite prior treatments including a specific type of targeted drug (a CDK4/6 inhibitor). It aims to find out if taking the drug ela…
Matched conditions: ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Doctors test 'Adaptive' chemo that adjusts dose based on tumor response
Disease control Recruiting nowThis study is testing a flexible approach to chemotherapy for advanced breast cancer that has spread. Researchers want to see if adjusting the dose of the drug capecitabine based on how the tumor responds—using scans and blood tests—can help control the cancer longer while possib…
Matched conditions: ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 23, 2026 15:29 UTC
-
New hope for Tough-to-Treat breast cancer: two drugs vs. one
Disease control Recruiting nowThis study is testing if combining two drugs, capecitabine and elacestrant, works better than just capecitabine alone for people with advanced, hormone-sensitive breast cancer. It's for patients whose cancer has stopped responding to a common class of prior medications. The main …
Matched conditions: ESTROGEN RECEPTOR POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC